PsychoGenics Inc.

PsychoGenics, a leader in preclinical neurobiology and in the provision of CNS drug discovery solutions, helps pharmaceutical companies and not-for-profit organizations to validate targets and select compounds to advance in clinical trials.

The company is transforming drug discovery with its proprietary, high throughput behavioral testing platforms, which combine expertise in behavioral neurobiology with the power of bioinformatics. The company's platform development is supported by an exclusive relationship with the National Robotics and Engineering Consortium at Carnegie Mellon University. These platforms are being used with PsychoGenics' battery of established behavioral tests to develop a pipeline of in-house and partnered drug candidates addressing such major CNS disorders as ADHD, anxiety, cognitive impairment, depression, eating disorders, pain and psychosis/schizophrenia.

PsychoGenics' management comprises research and business development experts in the fields of chem- and psychopharmacology, robotics and bioinformatics. Twenty-seven of the 100+ member research staff have Ph.D.s and the vast majority have extensive pharmaceutical industry experience. All research is conducted at PsychoGenics’ AAALAC compliant facilities in New York and Europe.